Pringl L Miller, MD | |
450 E 1000 N, North Salt Lake, UT 84054-1930 | |
(801) 548-3013 | |
Not Available |
Full Name | Pringl L Miller |
---|---|
Gender | Female |
Speciality | Surgery |
Location | 450 E 1000 N, North Salt Lake, Utah |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1184642167 | NPI | - | NPPES |
P01383991 | Other | WA | RAILROAD |
00A699350 | Medicaid | CA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208600000X | Surgery | MD00043763 (Washington) | Secondary |
208600000X | Surgery | A69935 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Pringl L Miller, MD 450 E 1000 N, North Salt Lake, UT 84054-1930 Ph: () - | Pringl L Miller, MD 450 E 1000 N, North Salt Lake, UT 84054-1930 Ph: (801) 548-3013 |
News Archive
A complex autoimmune disease, rheumatoid arthritis (RA) is characterized by chronic inflammation and progressive joint damage. This process begins with hyperplasia, or excessive increase in size and thickness, of synovial tissue. Along with provoking cartilage and bone destruction, this abnormal tissue growth is resistant to apoptosis, the natural cell death vital to the generation of healthy new cells.
A new analysis from Canada has found that cancer patients from poorer communities have a greater chance of dying prematurely than individuals from more affluent backgrounds even though cancer stage at time of diagnosis is similar across socioeconomic groups. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that efforts are needed to understand and reduce disparities in the survival of cancer patients from different socioeconomic groups.
Pepscan Therapeutics, the Netherlands based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced that it has signed a Research and License Agreement with Tibotec Pharmaceuticals, Ireland. Under the agreement Pepscan using its CLIPS technology will work with Tibotec to develop novel therapeutic peptides against an undisclosed target.
Community Health Systems, Inc. today announced financial and operating results for the three and six months ended June 30, 2012.
› Verified 2 days ago